<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03382912</url>
  </required_header>
  <id_info>
    <org_study_id>AM0010-202</org_study_id>
    <nct_id>NCT03382912</nct_id>
  </id_info>
  <brief_title>Study of AM0010 With Nivolumab Compared to Nivolumab Alone Second-line Tx in Patients With Metastatic Non-Small Cell Lung Cancer</brief_title>
  <acronym>Cypress 2</acronym>
  <official_title>A Randomized Phase 2 Trial of AM0010 in Combination With Nivolumab vs. Nivolumab Alone as Second-Line Therapy in Subjects With Stage IV / Metastatic Wild Type Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ARMO BioSciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ARMO BioSciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the efficacy of AM0010 in combination with nivolumab versus nivolumab alone in
      patients with metastatic Non-Small Cell Lung Cancer as measured by objective response rate
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, multi-center, randomized, Phase 2 study designed to compare the
      efficacy and safety of AM0010 in combination with Nivolumab versus Nivolumab alone in
      patients with stage IV / metastatic wild type Non-Small Cell Lung Cancer and tumors with low
      tumor expression of PD-L1 (0-49%)
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 14, 2018</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>36 months after the last patient randomized</time_frame>
    <description>The primary endpoint of this study is ORR defined as the proportion of patients who achieve a CR or PR as assessed by RECIST v.1.1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>36 months after the last patient randomized</time_frame>
    <description>OS defined as the time from date of randomization to death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>36 months after the last patient randomized</time_frame>
    <description>PFS defined as the time from date of randomization to the earlier of first documentation of disease progression or death due to any cause</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AM0010 self-administered as a SQ injection QD (≤ 80kg body weight = 0.8mg or [0.2mL] &gt; 80kg body weight = 1.6mg [0.4mL]). Nivolumab will be administered as intravenous (IV) infusion on Day 1 of a 14-day cycle (240mg over 30 minutes (± 10min))</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nivolumab will be administered as an intravenous (IV) infusion on Day 1 of a 14-day cycle (240mg over 30 minutes (± 10min))</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AM0010</intervention_name>
    <description>AM0010 plus Nivolumab</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Nivolumab Alone</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients must have histologically or cytologically confirmed WT NSCLC that is stage IV
             / metastatic or recurrent

          2. Patients must have received at least one prior systemic therapy that was not an
             anti-PD-1, anti-PD-L1 and/or anti-CTLA-4 treatment for the advanced stage of the
             disease

          3. Patients with tumor tissue low expression of PD-L1 as defined by Tumor Proportion
             Score (TPS) 0% - 49%

          4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

          5. Patients with measurable disease by spiral computed tomography (CT) or magnetic
             resonance imaging (MRI) per Response Evaluation Criteria in Solid Tumor (RECIST) v.1.1
             criteria

          6. Patients that have completed prior radiotherapy or radiosurgery at least 2 weeks prior
             to randomization

        Exclusion Criteria:

          1. Patients with active central nervous system (CNS) metastases or carcinomatous
             meningitis

          2. Patients with any serious or uncontrolled medical disorder or active infection with
             the hepatitis virus or the human immunodeficiency virus (HIV)

          3. Patients with Grade 1 (NCI-CTCAE v.4.03) toxicities attributed to prior anti-cancer
             therapy (other than alopecia and fatigue) prior to randomization

          4. Patients that have received nivolumab

          5. Patients that have received therapy with anti-tumor vaccines or other
             immuno-stimulatory antitumor agents

          6. Patients with a history of severe hypersensitivity reactions to monoclonal antibodies

          7. Patients that have received therapy with anti-PD-1, anti-PD-L1, anti-PD-L-2,
             anti-CD-137, and/or anti CTLA-4 antibodies

          8. Patients receiving any investigational agent within 28 days of first administration of
             trial treatment

          9. Pregnant or lactating women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Study Director</last_name>
    <phone>650-771-9325</phone>
    <email>Cypress2@armobio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beverly Hills Cancer Center</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ali Muhammad</last_name>
      <phone>310-432-8934</phone>
    </contact>
    <investigator>
      <last_name>David Berz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Joseph Heritage Hospital</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <zip>92835</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Noli Raz</last_name>
      <phone>714-446-5642</phone>
    </contact>
    <investigator>
      <last_name>William Lawler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Los Angeles Hematology Oncology Medical Group</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90017</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Macias</last_name>
      <phone>213-977-1214</phone>
      <phone_ext>727</phone_ext>
    </contact>
    <investigator>
      <last_name>Lasika Seneviratne, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Joseph Heritage Healthcare</name>
      <address>
        <city>Santa Rosa</city>
        <state>California</state>
        <zip>95403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabine Ucik</last_name>
      <phone>707-521-3830</phone>
    </contact>
    <investigator>
      <last_name>Ian Anderson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Innovative Clinical Research Institute (ICRI)</name>
      <address>
        <city>Whittier</city>
        <state>California</state>
        <zip>90603</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kirsten Bettino</last_name>
      <phone>562-693-4477</phone>
    </contact>
    <investigator>
      <last_name>Merrill K Shum, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbus Regional Research Institute</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31904</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Courtney Alexander</last_name>
      <phone>706-478-7968</phone>
    </contact>
    <investigator>
      <last_name>Andrew Pippas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Orchard Healthcare Research Inc.</name>
      <address>
        <city>Skokie</city>
        <state>Illinois</state>
        <zip>60077</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joy Jardinico</last_name>
      <phone>224-534-7580</phone>
    </contact>
    <investigator>
      <last_name>Ira Oliff, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Goshen Center for Cancer Care</name>
      <address>
        <city>Goshen</city>
        <state>Indiana</state>
        <zip>46526</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renee Moore</last_name>
      <phone>574-364-2439</phone>
    </contact>
    <investigator>
      <last_name>Ebenezer A Kio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Frederick Regional Health System James M Stockman Cancer Institute</name>
      <address>
        <city>Frederick</city>
        <state>Maryland</state>
        <zip>21702</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hema DiMaggio, RN</last_name>
      <phone>240-566-4941</phone>
    </contact>
    <investigator>
      <last_name>Elhamy Eskander, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Mintoff</last_name>
      <phone>313-916-3721</phone>
    </contact>
    <investigator>
      <last_name>Igor Rybkin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hattiesburg Clinic Hematology/Oncology</name>
      <address>
        <city>Hattiesburg</city>
        <state>Mississippi</state>
        <zip>39401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tammy McBeth</last_name>
      <phone>601-288-2495</phone>
    </contact>
    <investigator>
      <last_name>John Hrom, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Research Alliance, Inc.</name>
      <address>
        <city>Lake Success</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Colleen Kats</last_name>
      <phone>516-488-2918</phone>
      <phone_ext>121</phone_ext>
    </contact>
    <investigator>
      <last_name>Morton Coleman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Winthrop University Hospital and Clinics</name>
      <address>
        <city>Mineola</city>
        <state>New York</state>
        <zip>11501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Brown</last_name>
      <phone>516-663-3115</phone>
    </contact>
    <investigator>
      <last_name>Jeffrey Schneider, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southeastern Medical Oncology Center</name>
      <address>
        <city>Jacksonville</city>
        <state>North Carolina</state>
        <zip>28546</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elaine Cooke</last_name>
      <phone>910-353-0824</phone>
    </contact>
    <investigator>
      <last_name>Nagesh Jayaram, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gabrail Cancer Center Research</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Destiny Eblen</last_name>
      <phone>330-492-3345</phone>
      <phone_ext>207</phone_ext>
    </contact>
    <investigator>
      <last_name>Nashat Y Gabrail, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Christ Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linda Martin</last_name>
      <phone>513-585-1777</phone>
    </contact>
    <investigator>
      <last_name>Manish Bhandari, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Toledo</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43614</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Smiddy, RN</last_name>
      <phone>419-383-6962</phone>
    </contact>
    <investigator>
      <last_name>John J Nemunaitis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Millennium Oncology</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77090</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Waldron</last_name>
      <phone>877-870-2640</phone>
    </contact>
    <investigator>
      <last_name>Anirudha Dasgupta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 18, 2017</study_first_submitted>
  <study_first_submitted_qc>December 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 26, 2017</study_first_posted>
  <last_update_submitted>May 22, 2018</last_update_submitted>
  <last_update_submitted_qc>May 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

